EQT's portfolio company Karo Intressenter has placed a public bid for all outstanding shares in Karo Pharma at SEK 5.97bn. Karo Pharma is a specialty pharmaceutical company which develops and markets products for pharmacies and the health care sector. With EBITDA of SEK 142m in 2017, the bid value corresponds to an EV/EBITDA of 46.3x. Earlier in 2018, Karo acquired a smaller product portfolio from LEO Pharma.
